Potential mechanisms for cancer resistance in elephants and comparative cellular response to DNA Damage in Humans

JAMA - Journal of the American Medical Association

Volumn 314, Issue 17, 2015, Pages 1850-1860

  Abegglen, Lisa M ^a   Caulin, Aleah F ^b   Chan, Ashley ^a   Lee, Kristy ^a   Robinson, Rosann ^a   Campbell, Michael S ^a   Kiso, Wendy K ^c   Schmitt, Dennis L ^c   Waddell, Peter J ^d   Bhaskara, Srividya ^a,e   Jensen, Shane T ^b,f   Maley, Carlo C ^g,h   Schiffman, Joshua D ^a,e  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Ringling Bros Center for Elephant Conservation   (United States)

^d RONIN INSTITUTE   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g ARIZONA STATE UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPSY; BODY SIZE; CANCER MORTALITY; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; ELEPHANT; ELEPHAS MAXIMUS; FAMILIAL CANCER; GENE DOSAGE; GENE FREQUENCY; GENE SEQUENCE; GENOME; HUMAN; HUMAN CELL; IN VITRO STUDY; LIFESPAN; LOXODONTA AFRICANA; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; ANIMAL; CASE CONTROL STUDY; COMPARATIVE STUDY; DISEASE RESISTANCE; DNA REPAIR; EVOLUTION; GENETICS; IONIZING RADIATION; LYMPHOCYTE; MAMMAL; MORTALITY; NEOPLASM;

DOXORUBICIN;

ANIMALS; APOPTOSIS; BIOLOGICAL EVOLUTION; CASE-CONTROL STUDIES; DISEASE RESISTANCE; DNA DAMAGE; DNA REPAIR; DOXORUBICIN; ELEPHANTS; GENES, P53; HUMANS; LI-FRAUMENI SYNDROME; LYMPHOCYTES; MAMMALS; NEOPLASMS; RADIATION, IONIZING;

EID: 84946035099     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.13134     Document Type: Article

References (40)

1. Tomasetti C, Vogelstein B. Cancer etiology: variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science. 2015;347(6217):78-81.
2. Caulin AF, Maley CC. Peto's Paradox: evolution's prescription for cancer prevention. Trends Ecol Evol. 2011;26(4):175-182.
3. Peto R, Roe FJC, Lee PN, Levy L, Clack J. Cancer and ageing in mice and men. Br J Cancer. 1975;32 (4):411-426.
4. Tian X, Azpurua J, Hine C, et al. High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature. 2013;499(7458):346-349.
5. Gorbunova V, Hine C, Tian X, et al. Cancer resistance in the blind mole rat is mediated by concerted necrotic cell death mechanism. Proc Natl Acad Sci U S A. 2012;109(47):19392-19396.
6. Seluanov A, Hine C, Bozzella M, et al. Distinct tumor suppressor mechanisms evolve in rodent species that differ in size and lifespan. Aging Cell. 2008;7(6):813-823.
7. Hollstein M, Sidransky D, Vogelst ein B, Harris CC. p53 mutations in human cancers. Science. 1991;253 (5015):49-53.
8. Lane DP. p53, Guardian of the genome. Nature. 1992;358(6381):15-16.
9. Hanaha n D,Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
10. McBride KA,Ballinger ML,Killick E,et al Li-Fraumeni syndrome: cancer risk assessment and clinical management Nat Rev Clin Oncol 2014 11 5 260-271.
11. Testa JR, Malkin D, Schiffman JD. Connecting molecular pathways to hereditary cancer risk syndromes. Am Soc Clin Oncol Educ Book. 2013:81-90.
12. Griner LA. Pathology of Zoo Animals. San Diego, CA: Zoological Society of San Diego; 1983.
13. deMagalhães JP, Costa J. A database of vertebrate longevity records and their relation to other life-history traits. J Evol Biol. 2009;22(8): 1770-1774.
14. Elephant Encyclopedia. 1995-2012. http://www .elephant.se. Accessed November 2012.
15. Calabrese P, Shibata D. A simple algebraic cancer equation: calculating how cancersmay arise with normal mutation rates. BMC Cancer. 2010;10:3.
16. Macleod KF, Sherry N, Hannon G, et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 1995;9(8):935-944.
17. Yoon H, Liyanarachchi S,Wright FA, et al. Gene expression pro filing of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. Proc Natl Acad Sci U S A. 2002; 99(24):15632-15637.
18. Heinrichs S, DeppertW. Apoptosis or growth arrest: modulation of the cellular response to p53 by proliferative signals. Oncogene. 2003;22(4):555-571.
19. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74(6): 957-967.
20. Antoccia A, Sgura A, Berardinelli F, et al. Cell cycle perturbatio ns and genotoxic effects in human primary fibroblasts induced by low-energy protons and x/gamma-rays. J Radiat Res. 2009;50 (5):457-468.
21. Kastan MB, Zhan Q, el-DeiryWS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 1992;71(4):587-597.
22. Attardi LD, de Vries A, Jacks T. Activation of the p53-dependent G1 checkpoint res ponse in mouse embryo fibroblasts depends on the specific DNA damage inducer. Oncogene. 2004;23(4):973-980.
23. Peto R. Epidemiology, multistage models, and short-term mutagenicity tests. Paper presented at: The Origins of Human Cancer, Cold Spring Harbor Conferences on Cell Proliferation; 1977; Cold Spring Harbor, NY.
24. Nunney L. Lineage selection and the evolution of multistage carcinogenesis. Proc Biol Sci. 1999; 266(1418):493-498.
25. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-E386.
26. Bates S, Vousden KH. p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev. 1996;6(1):12-18.
27. Lakin ND, Jackson SP. Regu lation of p53 in response to DNA damage. Oncogene. 1999;18(53): 7644-7655.
28. Tyner SD, Venkatachalam S, Choi J, et al. p53 mutant mice that display early ageing-Associated phenotypes. Nature. 2002;415 (6867):45-53.
29. García-Cao I, García-Cao M, Martín-Caballero J, et al. " Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 2002;21(22):6225-6235.
30. Holliseter-Smith JA, Poole JH, Archie EA, et al. Age, musth and paternity success in wild male African elephants, Loxodonta africana. Anim Behav. 2007;74:287-296.
31. McComb K, Shannon G, Durant SM, et al. Leadership in elephants: the adaptive value of age. Proc Biol Sci. 2011;278(1722):3270-3276.
32. Pei B,Sisu C,Frankish A,et al The GENCODE pseudogene resource Genome Biol 2012 13 9 R51.
33. Pink RC, Wicks K, Caley DP, Punch EK, Jacobs L, Carter DR. Pseudogenes: pseudo-functional or key regulators in health and disease? RNA. 2011;17(5): 792-798.
34. Caulin AF, Graham TA,Wang LS, Maley CC. Solutions to Peto's paradox revealed by mat hematical modelling and cross-species cancer gene analysis. Philos Trans R Soc Lond B Biol Sci. 2015;370(1673):370.
35. Rohland N, Malaspinas AS, Pollack JL, Slatkin M, Matheus P, Hofrei terM. Proboscidean mitogenomics: chronology and mode of elephant evolution using mastodon as outgroup. PLoS Biol. 2007;5(8):e207.
36. Eizirik E, MurphyWJ, O'Brien SJ. Molecular dating and biogeography of the early placental mammal radiation. J Hered. 2001;92(2):212-219.
37. Spaulding CC,Walford RL, Effros RB. The accumulation of non-replicative, non-functional, senescent T cells with age is avoided in calorically restrictedmice by an enhancement of T cell apoptosis. Mech Ageing Dev. 1997;93(1-3):25-33.
38. Camplejohn RS, Gilchrist R, Easton D, et al. Apoptosis, ageing and cancer susceptibility. Br J Cancer. 2003;88(4):487-490.
39. Singh NP, Muller CH, Berger RE. Effects of age on DNA double-strand breaks and apoptosis in human sperm. Fertil Steril. 2003;80(6):1420-1430.
40. Wiese R, Willis K. Calculation of longevity and life expectancy in captive elephants. Zoo Biol. 2004;23:365-373.